United Therapeutics Corp. (UTHR) Provides Update for 2022 Oppenheimer Sees Material Catalysts

January 12, 2022 8:49 AM EST Send to a Friend
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $275.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) after listening ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login